THRD · CIK 1923840
What Third Harmonic Bio, Inc. told the SEC could break it.
Third Harmonic Bio's disclosures describe an early, single-asset biotech whose entire value rests on one candidate clearing regulatory hurdles. It is clinical-stage and pre-revenue — a $45.5M net loss and $159.7M accumulated deficit at year-end 2024, with no product expected to generate revenue for years — and its prospects hinge on FDA and ex-U.S. approval of its lead candidate THB335, with future economics further exposed to IRA drug-pricing and Medicare negotiation. That core asset is built on intellectual property licensed from Novartis (carrying royalty, milestone and diligence obligations), and because it owns no manufacturing it depends on contract manufacturers in the U.S., China and Europe, adding supply and U.S.–China policy risk.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Other disclosures
- clinical-stage, pre-revenue; $159.7M accumulated deficit; single lead candidate (THB335)medium
Third Harmonic has no commercialized products or revenue (and doesn't expect any for years), had a $45.5M net loss and $159.7M accumulated deficit at year-end 2024, and depends on its lead candidate THB335 (FDA IND cleared May 2024, first-in-human) amid a going-concern evaluation and strategic review.
“We have not yet commercialized any product candidates, and we do not expect to generate revenue from sales of any product candidates or from other sources for several years, if at all. As of December 31, 2024, we had $285.1 million in cash and cash equivalents, and we had an accumulated deficit of $159.7 million.”
SEC filing →As of 2025 - dependence on Novartis-licensed KIT-inhibitor IP (royalties, milestones, diligence obligations)medium
Third Harmonic's lead program (THB335/KIT inhibitor) is built on intellectual property licensed from Novartis, with royalty/milestone payment obligations and a requirement to use commercially reasonable efforts to develop and commercialize in seven major markets — so loss of or non-compliance with the Novartis license would jeopardize its core asset.
“Under the Novartis Agreement, we are solely responsible for all research, development, regulatory and commercialization activities related to the Licensed Products. We are required to use commercially reasonable efforts to develop and seek regulatory approval for, and commercialize, at least one Licensed Product in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.”
Regulatory & policy
- FDA/ex-US approval of THB335 and IRA drug-pricing/Medicare negotiationhigh
Third Harmonic's commercialization depends on lengthy, uncertain FDA and ex-US (MHRA/EU) approval of THB335, and future economics are exposed to IRA drug-pricing measures including Medicare price negotiation and reimbursement constraints.
“While it is unclear how the IRA will be implemented, it will likely have a significant impact on the pharmaceutical industry and the pricing of pharmaceutical products.”
SEC filing →As of 2025
Supplier concentration
- reliance on third-party CDMOs (US, China, Europe) for drug substance/productmedium
Third Harmonic owns no manufacturing and relies on CDMOs in the US, China and Europe to make bulk drug substance, drug product and materials; this dependence (with some contract manufacturing in China) exposes it to supply disruption and US-China policy risk.
“We currently rely, and may continue to rely, on CDMOs, including in the United States, China and Europe, to manufacture bulk drug substances, drug products, raw materials, samples, components, or other materials and reports.”
SEC filing →As of 2025
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its suppliers
“Under the Novartis Agreement, we are solely responsible for all research, development, regulatory and commercialization activities related to the Licensed Products. We are required to use commercially reasonable efforts to develop and seek regulatory approval for, and commercialize, at least one Licensed Product in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Pursuant to the Novartis Agreement, we made a one-time payment of $0.4 million to Novartis and agreed to issue shares of preferred stock pursua”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch